Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitors (hif Phis) - Renal Disorders

Relevant Publications

Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.

Issue Release: 2024

Iron Deficiency in Newly Referred Patients With Chronic Renal Failure.

Issue Release: 2024

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease.

Issue Release: 2024

Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study.

Issue Release: 2024

Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia.

Issue Release: 2024

Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.

Issue Release: 2024

Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.

Issue Release: 2024

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance.

Issue Release: 2024

Comparative Analysis of Real-World Efficacy and Safety of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Kidney Transplant Recipients Versus Nontransplant Individuals: A Single-Center Study.

Issue Release: 2024

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.

Issue Release: 2024

A spotlight on using HIF-PH inhibitors in renal anemia.

Issue Release: 2024

Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.

Issue Release: 2024

PHD1-3 oxygen sensors in vivo-lessons learned from gene deletions.

Issue Release: 2024

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.

Issue Release: 2024

Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.

Issue Release: 2024

The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia.

Issue Release: 2024

Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia.

Issue Release: 2023

Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.

Issue Release: 2023

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors . erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.

Issue Release: 2023

Association of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors with Cardiovascular Events and Death in Dialysis Patients: A Systematic Review and Meta-Analysis.

Issue Release: 2023

What are the signs of nephrotoxicity to watch for?

What is Microalbuminuria?

What Treatments are Available for Glomerular Filtration Issues?

What Tests Diagnose Renal Disorders?

What is Proteinuria?

Why are Lifestyle Changes Important?

What Dietary Changes Should Be Made?

What Can the Results Indicate?

What is the future outlook for ARBs in Renal Disorders?

Can Renal Disorders be Prevented?

Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitors (hif Phis) - Renal Disorders

Relevant Publications

Partnered Content Networks

Relevant Topics